Get it on Google Play

Amylyx to present Phase 3 avexitide trial data at ObesityWeek 2026

October 6, 2026 8:01 AM EDT Send to a Friend
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) will present topline results from its Phase 3 LUCIDITY clinical trial of avexitide at the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login